Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

Leuk Lymphoma. 2009 Jan;50(1):114-8. doi: 10.1080/10428190802492415.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides
  • Chromosome Aberrations*
  • Chromosomes, Human / genetics*
  • Disease Progression
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Leukemia, Myeloid, Chronic-Phase / genetics*
  • Leukemia, Myeloid, Chronic-Phase / pathology
  • Neoplasm Staging
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Survival Rate
  • Time Factors
  • Trisomy / genetics

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate